



(51) International Patent Classification:

C07K 14/195 (2006.01) *A61K 39/102* (2006.01)
C07K 14/21 (2006.01) *A61K 39/104* (2006.01)
C07K 14/245 (2006.01) *C07K 16/12* (2006.01)
C07K 14/285 (2006.01) *G01N 33/68* (2006.01)
A61K 39/02 (2006.01) *A61K 38/16* (2006.01)

(21) International Application Number:

PCT/US2011/030212

(22) International Filing Date:

28 March 2011 (28.03.2011)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/318,743	29 March 2010 (29.03.2010)	US
61/347,362	21 May 2010 (21.05.2010)	US
61/397,891	16 June 2010 (16.06.2010)	US
61/454,972	21 March 2011 (21.03.2011)	US

(71) Applicants (for all designated States except US):

UNIVERSITY OF SOUTHERN CALIFORNIA [US/US];
 3740 McClintock Avenue, EEB 131, Los Angeles, California 90089-2561 (US). **THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL** [US/US]; Center for Microbial Pathogenesis, 700 Children's Drive W591, Columbus, Ohio 43205-2696 (US).

(72) Inventors; and

(75) **Inventors/Applicants** (for US only): **GOODMAN, Steven D.** [US/US]; c/o University of Southern California, 3740 McClintock Avenue, EEB 131, Los Angeles, California 90089-2561 (US). **BAKALETZ, Lauren O.** [US/US]; c/o Center for Microbial Pathogenesis, The Research Institute at Nationwide Children's Hospital, 700

Children's Drive W591, Columbus, Ohio 43205-2696 (US).

(74) **Agents: KONSKI, Antoinette F.** et al.; Foley & Lardner LLP, 975 Page Mill Road, Palo Alto, California 94304-1013 (US).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: COMPOSITIONS AND METHODS FOR THE REMOVAL OF BIOFILMS




FIG. 10A

(57) **Abstract:** This invention provides isolated or recombinant polypeptides that are useful to vaccinate individuals suffering from chronic/recurrent biofilm disease or as a therapeutic for those with an existing infection. The individuals immune system will then naturally generate antibodies which prevent or clear these bacteria from the host by interfering with the construction and or maintenance of a functional protective biofilm. Alternatively, antibodies to the polypeptides can be administered to treat or prevent infection. Bacteria that cannot form functional biofilms are more readily cleared by the remainder of the hosts immune system.